Xeris expects Q4 cashflow positive, 2023 revenue at high end of $160M-$165M

Xeris Biopharma Holdings, Inc.

2023-FY EPS reported -$0.45 revenue$163,914,000

Total revenue for FY 2023 expected at high end of prior $160M-$165M guidance.
Ending cash, equivalents & short-term investments >$72M, above $65M-$70M guidance.
Q4 2023 expected to be cashflow positive; Q4 & FY results on or about March 6, 2024.
2024 outlook: revenue growth, flat opex, declining burn, sufficient cash for obligations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xeris Biopharma Holdings, Inc. updated its the year ended December 31, 2023 guidance (reaffirmed).

Period: the year ended December 31, 2023
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

On January 4, 2024, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release announcing certain preliminary results for the year ended December 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.